TrialThe Lancet. Oncology2015

Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.

Alexandria T Phan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.